Results from a survey of medical cannabis patients showed that over 99% of patients confirmed they have reduced symptoms using medical cannabis.
Compassionate Certification Centers, a medical cannabis healthcare system, in collaboration with Affinity Bio Partners, a Clinical Research Organisation (CRO) and AI Health Outcomes, CannaBot, have announced the conclusion and publication of a medical cannabis focussed observational study in Pennsylvania.
This research evaluates thousands of subjects who are current or past participants in the Pennsylvania Medical Marijuana Program who were asked to answer a variety of questions based on their first-hand experience.
Independently, Compassionate Certification Centers and Affinity Bio Partners designed the patient questionnaire which was released to the patients through the CannaBot™. Patients provided their feedback on varying parameters – with results indicating 99.62% of patients surveyed were able to reduce symptoms using medical cannabis, and 63.73% of patients stating that they were able to identify the strain that is most effective for their needs.
Other parameters patients were surveyed about included (but are not limited to): demographics, product selection and use, preferred route of administration, cost assessment, and dispensary experience.
Dr Bryan Doner (CCC) and Christina DiArcangelo (ABP) said: “The goal of this retrospective Pennsylvania patient data collection analysis was to gather information, from a patient-based perspective, regarding the Pennsylvania State Medical Marijuana program from its inception through late 2019.
“This information and data, provided directly by the patients the state medical marijuana program is serving, is paramount to the programs continued success and growth.”
Read the results of the patient-based research study here.